About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The group’s basic and clinical research activity, above all, surrounds the fields of inflammation and repair, respiratory insufficiency and tissue hypoxia, and these fields complement one another and are connected through the study of conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, infections, transplants, pulmonary hypertension or sleep-related breathing disorders.
The group has an experimental research laboratory and a clinical research and clinical trial unit. It is made up of professionals from different specialties (pulmonologists, biologists, nurses, laboratory technicians, physiotherapists etc.). This multidisciplinary team provides an added value to the group and guarantees the existence of the critical mass necessary to carry out scientific projects.
Our group is a node that belongs to the CIBERES network (CIBER for respiratory diseases) and also works in collaboration with groups of the highest national and international prestige.
PMID: 32855225 Journal: EUROPEAN RESPIRATORY JOURNAL Year: 2021 Reference: Eur Respir J. 2021 Jan 5;57(1). pii: 13993003.01451-2020. doi: 10.1183/13993003.01451-2020. Print 2021 Jan. Impact factor: 16.671 Publication type: Paper in international publication Authors: Loebinger, Michael R, Polverino, Eva, Chalmers, James D, Tiddens, Harm A W M, Goossens, Herman, Tunney, Michael, Ringhausen, Felix C, Hill, Adam T, Pathan, Rashidkhan, Angyalosi, Gerhild et al. DOI: 10.1183/13993003.01451-2020
PMID: 33239552 Journal: JOURNAL OF HYPERTENSION Year: 2021 Reference: J Hypertens. 2021 Feb 1;39(2):302-309. doi: 10.1097/HJH.0000000000002664. Impact factor: 4.844 Publication type: Paper in international publication Authors: Navarro-Soriano, Cristina, Torres, Gerard, Barbe, Ferran, Sanchez-de-la-Torre, Manuel, Manas, Pedro, Lloberes, Patricia, Cambriles, Trinidad Diaz, Somoza, Maria, Masa, Juan F, Gonzalez, Monica et al. DOI: 10.1097/HJH.0000000000002664
PMID: 31843689 Journal: JOURNAL OF INFECTION Year: 2020 Reference: J Infect. 2020 Feb;80(2):190-196. doi: 10.1016/j.jinf.2019.12.006. Epub 2019 Dec 13. Impact factor: 4.842 Publication type: Paper in international publication Authors: Ferrer, Ricard, Nuvials, Xavier, Deu, Maria, Peghin, Maddalena, Gonzalez-Lopez, Juan Jose, Lung, Mayli, Roman, Antonio, Gavalda, Joan, Len, Oscar, Berastegui, Cristina et al. DOI: 10.1016/j.jinf.2019.12.006
PMID: 32021623 Journal: Allergy Asthma and Clinical Immunology Year: 2020 Reference: Allergy Asthma Clin Immunol. 2020 Jan 30;16:7. doi: 10.1186/s13223-020-0404-8. eCollection 2020. Impact factor: 2.104 Publication type: Paper in international publication Authors: Clofent, David, de Homdedeu, Miquel, Munoz-Esquerre, Mariana, Cruz, Maria Jesus, Munoz, Xavier et al. DOI: 10.1186/s13223-020-0404-8
PMID: 31992414 Journal: Journal of Clinical Sleep Medicine Year: 2020 Reference: J Clin Sleep Med. 2020 Feb 15;16(2):243-250. doi: 10.5664/jcsm.8174. Epub 2020 Jan 13. Impact factor: 3.586 Publication type: Paper in international publication Authors: Riba-Llena, Iolanda, Alvarez-Sabin, Jose, Romero, Odile, Santamarina, Estevo, Sampol, Gabriel, Maisterra, Olga, Ferre, Alex, Montaner, Joan, Quintana, Manuel, Delgado, Pilar et al. DOI: 10.5664/jcsm.8174
PMID: 31929536 Journal: PLoS One Year: 2020 Reference: PLoS One. 2020 Jan 13;15(1):e0226488. doi: 10.1371/journal.pone.0226488. eCollection 2020. Impact factor: 2.74 Publication type: Paper in international publication Authors: Berastegui, Cristina, Gomez-Olles, Susana, Mendoza-Valderrey, Alberto, Pereira-Veiga, Thais, Culebras, Mario, Monforte, Victor, Saez, Berta, Lopez-Meseguer, Manuel, Sintes-Permanyer, Helena, Ruiz de Miguel, Victoria et al. DOI: 10.1371/journal.pone.0226488
PMID: 29301926 Journal: EUROPEAN RESPIRATORY JOURNAL Year: 2018 Reference: Eur Respir J. 2018 Jan 4;51(1). pii: 51/1/1702033. doi: 10.1183/13993003.02033-2017. Print 2018 Jan. Impact factor: 12.242 Publication type: Letter or abstract Authors: Chalmers, James D, Polverino, Eva et al. DOI: 10.1183/13993003.02033-2017
PMID: 28811074 Journal: Transplantation Reviews Year: 2018 Reference: Transplant Rev (Orlando). 2018 Jan;32(1):36-57. doi: 10.1016/j.trre.2017.07.001. Epub 2017 Jul 26. Impact factor: 2.364 Publication type: Clinical guide Authors: Martin-Davila, P, Montejo, M, Moreno, A, Oliver, A, Pascual, A, Perez-Nadales, E, Roman-Broto, A, San-Juan, R, Seron, D, Sole-Jover, A et al. DOI: 10.1016/j.trre.2017.07.001
Vall d'Hebron participated in the study in which more than half of the patients who received treatment with bacteriophages experienced significant improvements
La recerca és fonamental per contrarestar els efectes de la pol·lució, que segons l’AEMPS, va ser la causa de més de 300.000 morts prematures a la UE el 2020.
Pulmonary hypertension is a risk factor for patients who need surgery and, therefore, defining strategies for its management is important to allow a favorable clinical evolution.
EXIMIOUS (Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome), un projecte finançat per la Unió Europea que engloba 15 organitzacions de 7 països europeus.
EXIMIOUS té com a objectiu estudiar l’exposoma, és a dir, l’exposició a factors ambientals al llarg de la vida, per entendre la seva relació amb les malalties immunomediades, com ara les malalties autoimmunes o les al·lèrgies. Des del VHIR està liderat per la Dra. M Jesús Cruz i el seu equip de Pneumologia.
